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Ruxolitinib is a novel selective JAK 1/2 inhibitor approved for the treatment 
of myelofibrosis (MF) and polycythemia vera (PCV). Hypocalcemia 
associated with ruxolitinib has not been reported in early trials or in 
literature. It has a target specific action with JAK1/2 receptor and based 
on current evidence there is lack of interaction with JAK3 receptor which 
has a role in calcium homeostasis.
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The JAK family comprises of a group of tyrosine kinases JAK1, JAK2, JAK3 and TYK2. The JAK family plays a vital role in maintaining normal hematopoietic function. Ruxolitinib 
has a target specific action on JAK1/2 receptor and currently there is no evidence to suggest JAK3 receptor interaction.1-3 The temporal relation of ruxolitinib initiation to the drop 
in counts and hypocalcemia was evident in our case. Once drug was discontinued, hypocalcemia persisted for 4 weeks until calcium replacement initiated. There is only one 
reported case of hypocalcemia after ruxolitinib initiation where patient presented with tumor lysis, acute renal failure and hyperphosphatemia. Tumor lysis improved with expectant 
management however hypocalcemia persisted.4 Interestingly the JAK pathway is associated with Calcium homeostasis, phosphate and Vitamin D metabolism. Studies have 
shown JAK3 deficiency is associated with increase in 1,25 OH-D3 with resultant increase in intestinal phosphate absorption and inhibition of PTH production.5,6 Our patient had 
hypoparathyroidism and the resultant hyperphophatemia was managed with phosphate binders and maintained stable with in normal value for many years. With ruxolitinib, it is 
unclear if there can be heightened sensitiveness to JAK3 receptor inhibition in specific population with concomitant parathyroid abnormalities. Another hypothesis is the interaction 
of JAK- STAT pathway with EGFR and PDGFR which play a role in osteoblast differentiation and fracture repair respectively. The exact role of such interactions at present is 
intangible and would require further studies.
The case highlights a unique association of ruxolitinib to hypocalcemia. It is to yet to be proven whether this was a chance occurrence or a direct causal effect, however it is 
important to keep this association in mind since ruxolitinib is increasingly being used for myelofibrosis and polycythemia patients. 
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A 65-year female presented with complaints of severe myalgia, fatigue, 
paresthesias of fingers and toes and a critical hypocalcemia. She has 
a history of CKD stage 3, PCV (since 1989), papillary thyroid carcinoma 
status post total thyroidectomy (1996), mild hypoparathyroidism (1996) 
from her thyroid surgery with associated hyperphosphatemia, which was 
managed successfully with phosphate binders for years. Her current blood 
work showed a corrected S. Ca 5.8 mg /dl (8.9-10.1 mg/dL) and ionised 
Ca 2.9 mg/dl (4.5 - 5.4 mg/dL). Other labs showed stable creatinine 
1.5 mg/dL, intact PTH 29 pg/ml(14-72pg/ml) and 25,OH vitamin D level 
35ng/ml (30-100ng/ml). She was diagnosed with PCV in 1989 and her 
peripheral blood counts were adequately controlled with intermittent 
phlebotomies and hydroxyurea up until 4 months ago. She was started on 
ruxolitinib 4 months ago due to progressive elevation of WBC and platelet 
counts above 40 x 103 cells/ mm3 and 1.5 million cells/ mm3 respectively. 
Follow up labs showed rapid fall in peripheral blood counts requiring 
discontinuation of ruxolitinib ( Table 1). She had noticed her current 
symptoms since the start of ruxolitinib and continued to have symptoms 
even after stopping the drug. Her symptoms were attributed to very 
low S. Ca level. She was treated with intravenous calcium and once her 
phosphorus level was below 5.5mg/dl,  calcitriol was started. The Ca level 
corrected and was discharged on oral calcium carbonate, calcium acetate 
and calcitriol.
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Table 1. Laboratory Results


















6.0 5.3 <5 9.3
S.Phos (2.5-4.5 mg/dL) 4.1     7.1 3.9
Hb (12.1 - 14.5 g/dL) 11.6 12.9 10.7 6.8 8.5 9.7 10.4 11.0
Hct 38.5 39.7 32.4 21.8 26.9 31.6 32.8 34
WBCx103 cell/mm3 (4.5-10) 50.1 7.1 8.7 7.6 11.5 17.0 21.9 27.3
Plateletx103 cells/mm3 (150-350) 733 169 104 73 244 779 714 592
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